China's Biotech Industry

China's startup NeuroXess is building a factory to mass-produce BCI in the second half of this year.

$5.6 billion deal for a cancer drug that can potentially treat some type of lung cancer and colorectal cancer:

JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement​

Under the agreement, AbbVie will hand over $650m in upfront payments, while committing to pay up to $4.95bn if the therapy meets certain regulatory, development and commercial milestones.

In exchange, RemeGen will grant AbbVie the exclusive development, manufacturing and commercialisation rights to RC148 outside of the Greater China region. RemeGen will be entitled to receive tiered, double-digit royalties on net sales outside of Greater China if RC148 were to make it to market.

Click to expand...

Recently, a Chinese research team successfully treated patients with autoimmune hemolytic anemia (AIHA) who had failed multiple lines of drug therapy using their independently developed autologous CD19 CAR T cells, providing a new salvage treatment option for patients who have failed conventional drug therapy.

On January 15th, the research findings of the team led by Shi Jun and Xiong Haiqing from the Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology) were published online in the *New England Journal of Medicine*, marking a new breakthrough in innovative cell and gene therapy in my country's regenerative medicine field.

It is understood that AIHA is an autoimmune hematologic disorder caused by autoantibodies attacking red blood cells, leading to accelerated red blood cell destruction and anemia. It has a high incidence and prevalence, with about half of patients progressing to a relapsed or refractory state. It can cause serious infections, sepsis, vascular embolism, etc., with a disability and mortality rate as high as 20%.

tphuang said:

https://twitter.com/i/web/status/2010482787954925949

HengRui Pharma is the most prolific of the Chinese BioTech firms in the past few years. GSK out licensing deal was for $12.5B with $500m up front

Click to expand...

Seems biotech industry can grow to match auto industry in future and profits margins are far larger. So good thing for Chinese companies. Guess many educated youths would be going more and more into this industry in future.

A French surgical team visited a hospital in south China's Guangzhou to observe advanced robotic surgery techniques.

He doesn’t like China’s rise in biotech because he doesn’t get to decide which diseases get the attention therefore where the money goes. You know what they don’t talk about? White people have many and different genetic rare diseases. Maybe that’s why he thinks China is not going to study and develop cures for rare diseases because they go for what the majority of people experience. Why is that? Remember, the Black Plague wiped out a significant portion of the European population. Back then if a family member got it, it meant the whole family was open to infection just for being in proximity. So entire families were wiped out. That opens society to interbreeding since people had to stay away from others to be safe. What are the dangers of interbreeding? Genetic anomalies hence why rare diseases form and pass genetically. You can see why they don’t talk about it because if it were someone else, they would never let go labeling someone with that Scarlet Letter especially when one likes to believe they’re genetically superior.